Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Salem Media Group Files For $40M Mixed-Securities Shelf Offering

-Reuters
byMichael Horton
October 3, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

-Reuters

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

AstraZeneca And Daiichi Sankyo’s Datopotamab Deruxtecan Extended Progression-Free Survival Vs. Chemotherapy In Patients With HR-Positive, HER2-Low Or Negative Breast Cancer In TROPION-Breast01 Phase III Trial

By Benzinga Newsdesk
October 23, 10:31 AM
AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan reduced the risk of disease progression or death by 37%, providing a 2-month median PFS benefit, and was well tolerated in post-endocrine therapy settingPositive

AZN